Clinical Significance of Laboratory-determined Aspirin Poor Responsiveness After Primary Percutaneous Coronary Intervention

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  2016-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10557-016-6643-8PMID 26843365
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Door-to-balloon time and mortality among patients undergoing primary PCI.

  2013cited by this paper
• Adverse event rates following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial.

  2013cited by this paper
• Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial.

  2013cited by this paper
• High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial)

  2012cited by this paper
• Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period.

  2011cited by this paper
• High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.

  2011cited by this paper
• Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy

  2011cited by this paper
• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

  2011cited by this paper
• Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium

  2011cited by this paper
• Residual platelet reactivity after aspirin and clopidogrel treatment predicts 2-year major cardiovascular events in patients undergoing percutaneous coronary intervention.

  2011cited by this paper
• Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients.

  2010influential reference
• Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.

  2010cited by this paper
• Anti-platelet therapy and aspirin resistance - clinically and chemically relevant?

  2010cited by this paper
• Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.

  2010cited by this paper
• Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up

  2009cited by this paper
• Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy.

  2009cited by this paper
• Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

  2009cited by this paper
• Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.

  2009cited by this paper
• Letter by Klein Regarding Article, "Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study"

  2008influential reference
• Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk

  2008cited by this paper
• Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis

  2008cited by this paper
• Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction.

  2007influential reference
• Aspirin resistance and adverse clinical events in patients with coronary artery disease.

  2007cited by this paper
• Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis.

  2007cited by this paper
• Aspirin dose for the prevention of cardiovascular disease: a systematic review.

  2007cited by this paper
• Aspirin Resistance: Does It Exist?

  2007cited by this paper
• Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.

  2006cited by this paper
• The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events

  2006cited by this paper
• Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS

  2006cited by this paper
• Aspirin resistance or variable response or both?

  2006cited by this paper
• Residual Arachidonic Acid–Induced Platelet Activation via an Adenosine Diphosphate–Dependent but Cyclooxygenase-1– and Cyclooxygenase-2–Independent Pathway: A 700-Patient Study of Aspirin Resistance

  2006cited by this paper
• Stent thrombosis is associated with an impaired response to antiplatelet therapy.

  2005cited by this paper
• High frequency of aspirin resistance in patients with acute coronary syndrome.

  2005influential reference
• Platelet Function Predicts Myocardial Damage in Patients With Acute Myocardial Infarction

  2004cited by this paper
• Aspirin non-responder status in patients with recurrent cerebral ischemic attacks

  2003cited by this paper
• Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin.

  2002cited by this paper
• Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events

  2002cited by this paper
• Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate.

  2002cited by this paper
• Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.

  1993cited by this paper
• Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

  1982cited by this paper

• Inflammatory cell response following ST-elevation myocardial infarction treated with primary percutaneous coronary intervention and its impact on cardiovascular outcomes: A systematic review and meta-analysis.

  2023cites this paper
• Assessment of platelet function and resistance to aspirin and clopidogrel in patients with peripheral arterial disease undergoing percutaneous transluminal angioplasty

  2021cites this paper
• Effect of Dialysis on Antiplatelet Drug Efficacy in Uremic Patients with Coronary Heart Disease

  2017cites this paper
• Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients

  2017cites this paper
• Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome

  2016cites this paper